The Pharmaceutical Benefits Scheme (PBS) has recently expanded its coverage, offering new treatments for various medical conditions, including psoriasis and cystic fibrosis. One notable addition is Wynzora, a medication for chronic stable plaque-type psoriasis vulgaris, which can now be accessed by over 140,000 Australians. This development is expected to significantly improve the lives of these patients by slowing skin cell overgrowth and reducing inflammation and irritation. The cost of Wynzora without subsidy is approximately $65 per script, making it more affordable for those in need. Additionally, the Federal Government has also expanded access to dapagliflozin (Forxiga) for individuals with chronic kidney disease, benefiting around 65,000 people. This decision aligns with the recommendations of the Pharmaceutical Benefits Advisory Committee, ensuring equitable access to essential medications. Furthermore, a groundbreaking treatment for cystic fibrosis, Vanzacaftor with tezacaftor and deutivacaftor (Alyftrek), has been introduced to the PBS, offering hope to those with at least one mutation in the CF transmembrane conductance regulator (CFTR) gene. This oral medication, suitable for individuals aged six and above, increases the production of functional CFTR proteins. The addition of Alyftrek to the PBS follows the listing of elexacaftor/tezacaftor/ivacaftor (Trikafta) last July, further enhancing the treatment options for Australians living with cystic fibrosis. The introduction of these new treatments has the potential to revolutionize patient care, as previously, the cost of such treatments was prohibitively expensive, with some medications costing up to $250,000. The RACGP's poll on improving the experience of GPs in training reveals interesting priorities. A significant 53% of respondents believe that increasing the attractiveness and longevity of a general practice career is crucial. Other important considerations include better employment conditions during training (27%), more wellbeing supports (4%), a smoother transition from registrar to New Fellow (4%), and clear and consistent communications around training policies (10%). These insights highlight the need for comprehensive support and recognition to attract and retain talented individuals in the medical field.
